Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, November 18, 2019
AGC Biologics announced their development and manufacturing capabilities at their Seattle, Washington and Copenhagen, Denmark facilities will be expanded.
read more
AGC Biologics announced the addition of a new building complex that will house the company’s global headquarters in Bothell, Washington.
read more
Monday, December 16, 2019
AGC Biologics is expanding its CDMO services with plasmid DNA (pDNA) offerings from its Heidelberg site in Germany.
read more
AGC Biologics announces it has expanded its partnership with Rocket Pharmaceuticals.
read more
AGC Biologics has entered into a commercial supply agreement with MacroGenics for the manufacture of margetuximab, a clinical-stage, novel immune-optimized monoclonal antibody.
read more
Wednesday, August 09, 2023
AGC Biologics announced the completion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site.
read more
AGC Biologics will supply bulk drug substance for the launch of Portola Pharmaceuticals' Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo].
read more
AGC Biologics has announced the appointment of Christopher Holt as Site Head/General Manager of its Bothell, Washington operations.
read more
Tuesday, October 08, 2019
AGC Biologics announced the appointment of Jeffery D. Mowery as Site Head/General Manager of the Copenhagen, Denmark facility.
read more
AGC Biologics announced the appointment of Kasper Møller to the role of Chief Technical Officer.
read more
Monday, November 15, 2021
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced Jean-Baptiste Agnus has been appointed as the company’s Chief Business Officer (CBO). In this position, he is responsible for ...
read more
Robert Broeze will retire on March 5th, 2019 after a 35-year career in the biopharmaceutical industry.
read more
Thursday, October 23, 2025
AGC Biologics has entered into an agreement with Rarity PBC to develop and manufacture RDP-101, a breakthrough gene therapy targeting Adenosine Deaminase Severe Combined Immunodeficiency Disorder (ADA-SCID), also known as “Bubble Baby Disease”.
read more
Friday, December 16, 2022
AGC Biologics announced a collaboration with W.L. Gore & Associates that features Protein A affinity purification technology from Gore alongside the CDMO’s contract development and manufacturing services.
read more
AGC Biologics and BioConnection have announced a new strategic partnership. The companies are partnering to provide end- to-end biopharmaceutical development and manufacturing capabilities for drug substance and drug product using the development and...
read more